Peginterferon Lambda-1a Is Associated with a Low Incidence of Autoimmune Thyroid Disease in Chronic Hepatitis C

Journal of Interferon and Cytokine Research

Volumn 35, Issue 11, 2015, Pages 841-843

  Fredlund, Paul ^a   Hillson, Jan ^a   Gray, Todd ^a   Shemanski, Lynn ^a   Dimitrova, Dessislava ^a   Srinivasan, Subasree ^b  

^a BRISTOL MYERS SQUIBB   (United States)

^b BRISTOL MYERS SQUIBB RESEARCH AND DEVELOPMENT   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

LEVOTHYROXINE; PEGINTERFERON ALPHA; PEGINTERFERON LAMBDA; RIBAVIRIN; THIOUREA; THYROTROPIN; ALANINE AMINOTRANSFERASE; ALPHA INTERFERON; ANTIVIRUS AGENT; ASPARTATE AMINOTRANSFERASE; INTERLEUKIN DERIVATIVE; MACROGOL DERIVATIVE;

ADULT; AGED; ANTIVIRAL THERAPY; ARTICLE; AUTOIMMUNE DISEASE; AUTOIMMUNE THYROIDITIS; BRAIN PSEUDOTUMOR; CHRONIC HEPATITIS C; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; ENDOCRINOLOGIST; FEMALE; GRAVES DISEASE; HEPATITIS C VIRUS GENOTYPE 1; HEPATITIS C VIRUS GENOTYPE 2; HEPATITIS C VIRUS GENOTYPE 3; HEPATITIS C VIRUS GENOTYPE 4; HUMAN; HYPERTHYROIDISM; HYPOTHYROIDISM; MAJOR CLINICAL STUDY; MALE; MEDICAL DICTIONARY FOR REGULATORY ACTIVITIES; PANNICULITIS; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REFERENCE VALUE; RETROSPECTIVE STUDY; SARCOIDOSIS; SINGLE BLIND PROCEDURE; THYROID DISEASE; THYROIDITIS; THYROTROPIN BLOOD LEVEL; UVEITIS; ADOLESCENT; BLOOD; CHEMICALLY INDUCED; CLINICAL TRIAL; COMBINATION DRUG THERAPY; DOUBLE BLIND PROCEDURE; DRUG EFFECTS; HEPACIVIRUS; HEPATITIS C, CHRONIC; METABOLISM; MIDDLE AGED; TREATMENT OUTCOME; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; ALANINE TRANSAMINASE; ANTIVIRAL AGENTS; ASPARTATE AMINOTRANSFERASES; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; INTERFERON-ALPHA; INTERLEUKINS; MIDDLE AGED; POLYETHYLENE GLYCOLS; RETROSPECTIVE STUDIES; RIBAVIRIN; THYROIDITIS, AUTOIMMUNE; THYROTROPIN; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84946728644     PISSN: 10799907     EISSN: 15577465     Source Type: Journal    
DOI: 10.1089/jir.2014.0233     Document Type: Article

References (8)

1. Donnelly RP, Dickensheets H, O'Brien TR. 2011. Interferonlambda and therapy for chronic hepatitis C virus infection. Trends Immunol 32(9):443-450
2. Friborg J, Levine S, Chen C, Sheaffer AK, Chaniewski S, Voss S, Lemm JA, McPhee F. 2013. Combinations of lambda interferon with direct-acting antiviral agents are highly efficient in suppressing hepatitis C virus replication. Antimicrob Agents Chemother 57(3):1312-1322
3. Genentech USA September 2014. Pegasys® (pegylated interferon alfa-2a). Prescribing Information, Genentech, Inc., USA [Internet]; September 2014
4. Muir AJ, Arora S, Everson G, Flisiak R, George J, Ghalib R, Gordon SC, Gray T, Greenbloom S, Hassanein T, et al. 2014. A randomized phase 2b study of peginterferon lambda-1a for the treatment of chronic HCV infection. J Hepatol 61(6):1238-1246
5. Nair Kesavachandran C, Haamann F, Nienhaus A. 2013. Frequency of thyroid dysfunctions during interferon alpha treatment of single and combination therapy in hepatitis C virus-infected patients: a systematic review based analysis. PLoS One 8(2):e55364
6. Rodriguez-Torres M, Hillson JL, Bacon B, Box T, Hassanein T, Greenbloom S, Lawitz E, Vargas H, Vierling JM, Horga A, et al. 2011. Safety and efficacy of pegylated interferon lambda (lambda) compared to pegylated interferon a-2a (alfa-2a) in HCV-infected patients (G1/2/3) with compensated cirrhosis: EMERGE phase IIb efficacy and safety results through week 12. Hepatology 54 (4 suppl):994A-995A
7. Tran HA, Jones TL, Ianna EA, Foy A, Reeves GE. 2013. Thyroid disease in chronic hepatitis C infection treated with combination interferon-alpha and ribavirin: management strategies and future perspective. Endocr Pract 19(2):292-300
8. Watanabe U, Hashimoto E, Hisamitsu T, Obata H, Hayashi N. 1994. The risk factor for development of thyroid disease during interferon-alpha therapy for chronic hepatitis C. Am J Gastroenterol 89(3):399-403